Results 71 to 80 of about 15,566 (231)

Influence of Cyp3A4, Cyp3A5 and ABCB1 polymorphisms on tacrolimus concentrations and rejection risk in Indian kidney transplant recipients

Indian Journal of Transplantation
Background: Tacrolimus metabolism is known to be determined by gene polymorphisms. Cyp3A5 genotype has most widely been seen to be associated with tacrolimus metabolism. Studies on other genes have produced mixed results.
Kamal Kiran Mukkavilli, Mohammed Shoeb A Khan, Arun Kumar Donakonda, Suma Rama Gopal Gangisetty, Dileena Poojaveli   +4 more
doaj   +1 more source

Integrative Analysis of Plasma Proteome and Genome Reveals Novel Drug Targets for Chronic Rhinosinusitis and Nasal Polyps

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) and nasal polyps (NP) are chronic inflammatory conditions with unsatisfactory treatment outcomes due to frequent recurrence of refractory disease. Identifying new therapeutic targets is essential. Methods We conducted a proteome‐wide Mendelian randomization (MR) analysis by integrating genome‐wide ...
En Zhou, Shi Luo, Yu Xiao, Bin Liu, Xu‐Ping Xiao   +4 more
wiley   +1 more source

Optic nerve sheath meningioma exhibits neural niche‐associated transcriptomic features and rare copy number variation‐linked evolution

Brain Pathology, EarlyView.
Optic nerve sheath meningiomas are typically NF2‐intact with few copy number alterations and are generally clinically indolent. Rare aggressive recurrences are associated with progressive accumulation of copy number variations, including CDKN2A/B homozygous deletion, 1q gain, and 14q loss.
Daisuke Sato, Satoru Miyawaki, Yu Sakai, Kenta Ohara, Yu Teranishi, Yudai Hirano, Motoyuki Umekawa, Takahiro Tsuchiya, Shotaro Ogawa, So Hirata, Hiroki Hongo, Hideaki Ono, Daisuke Komura, Tetsuo Ushiku, Shumpei Ishikawa, Nobuhito Saito   +15 more
wiley   +1 more source

Variability in Expression of CYP3A5 in Human Fetal Liver [PDF]

Drug Metabolism and Disposition, 2015
Members of the cytochrome P450 3A (CYP3A) subfamily of drug metabolizing enzymes exhibit developmental changes in expression in human liver characterized by a transition between CYP3A7 and CYP3A4 over the first few years of life. In contrast, the developmental expression of CYP3A5 is less well understood due to polymorphic expression of the enzyme in ...
Carrie A, Vyhlidal, Robin E, Pearce, Roger, Gaedigk, Justina C, Calamia, Diana L, Shuster, Kenneth E, Thummel, J Steven, Leeder   +6 more
openaire   +2 more sources

Development and analytical validation of a targeted short‐read next generation sequencing‐based pharmacogenetic panel for comprehensive variant detection

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Genomic profiling of patients for genetic variants that modify the effect of specific medications has many benefits, including the possibility of avoiding toxicities and ensuring an adequate effect of the medication. Our intention was to develop a comprehensive, high‐quality pharmacogenetic test panel for clinical use ...
Anna Gréen, Nils Johan Fredriksson, Michael Andresen, Jon Jonasson, Malin Lindqvist Appell, Henrik Gréen   +5 more
wiley   +1 more source

Factors affecting the long-term response to tacrolimus in renal transplant patients: Pharmacokinetic and pharmacogenetic approach

International Journal of Medical Sciences, 2010
Background: The aim of our study was to determine the impact of CYP3A5*1 and CYP3A5*3 on the kinetics of tacrolimus in renal transplant recipients. Material and methods: Forty kidney recipients were selected to participate.
Paraskevi F. Katsakiori, Eirini P. Papapetrou, George C. Sakellaropoulos, Dimitrios S. Goumenos, George C. Nikiforidis, Christodoulos S. Flordellis
doaj  

Effect of CYP3A5*3 polymorphism on anti-inflamatory therapy in children with bronchial asthma

Медицинский совет, 2019
Previous pharmacogenetic studies demonstrate significant genes’ polymorphisms effect on the efficacy and safety of pharmacotherapy, including in bronchial asthma (BA).
A. K. Zastrozhina, S. V. Zaitseva, E. A. Grishina, K. A. Ryzhykova, O. O. Panfeorova, S. Y. Kalenov, O. I. Soboleva, D. A. Sychyov, I. N. Zakharova   +8 more
doaj   +1 more source

Unveiling Hepatic Protein Alterations in Neonatal and Infant Biliary Atresia

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1584-1596, June 2026.
Pediatric populations differ from adults in drug elimination capacity. While current scaling methods account for enzyme and transporter maturation, they overlook comorbidities, such as biliary atresia (BA), a liver disease appearing within the first 2–8 weeks of life that can progress to cirrhosis.
Zubida M. Al‐Majdoub, Martyn Howard, Brahim Achour, Jill Barber, Naved Alizai, Amin Rostami‐Hodjegan   +5 more
wiley   +1 more source

A Minimal Physiologically‐Based Pharmacokinetic Model for Tacrolimus in Living‐Donor Liver Transplantation: Perspectives Related to Liver Regeneration and the cytochrome P450 3A5 (CYP3A5) Genotype

CPT: Pharmacometrics & Systems Pharmacology, 2019
In adult patients after living‐donor liver transplantation, postoperative days and the cytochrome P450 3A5 (CYP3A5) genotype are known to affect tacrolimus pharmacokinetics.
Kotaro Itohara, Ikuko Yano, Tetsunori Tsuzuki, Miwa Uesugi, Shunsaku Nakagawa, Atsushi Yonezawa, Hideaki Okajima, Toshimi Kaido, Shinji Uemoto, Kazuo Matsubara   +9 more
doaj   +1 more source

Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: Recent developments and ethnic considerations [PDF]

, 2016
Introduction: Tacrolimus (Tac) is effective in preventing acute rejection but has considerable toxicity and inter-individual variability in pharmacokinetics and pharmacodynamics.
Andrews, L.M. (Louise), Gelder, T. (Teun) van, Hesselink, D.A. (Dennis), Schaik, R.H.N. (Ron) van, Shi, Y.Y. (Yunjing), Tang, J.T. (Jiang-Tao), Wang, L.L. (Lanlan)   +6 more
core   +3 more sources